drugset / Trial / NCT06518876
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, dose-escalation/expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic characteristics and determine the recommended dose of KQ-2003 CAR T-cells for patients with Relapsed/Refractory POEMS Syndrome
Timeline
- Start
- 2024-08-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KQ-2003 CAR T-cells | Cell therapy | 500000 cells/kg | — |
| Subject | KQ-2003 CAR T-cells | Cell therapy | 1e+06 cells/kg | — |
| Subject | KQ-2003 CAR T-cells | Cell therapy | 2e+06 cells/kg | — |